marked.bio

B7-H3 ADC ยท ADC

HS-20093

2 active trials across 2 of our biomarkers, targeting B7-H3. Not approved for any biomarker on marked.bio yet.

Also known as GSK5764227.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 2 2 Phase 1/2
KRAS G12D 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of HS-20093.

  1. Hansoh Pharma 1

Trials

2 of 2 trials shown

  1. A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

    Not yet recruiting Phase 1/2 Zhejiang University Started 2026Primary completion 2028-08 NCT07736612

    HRS-2329 TabletNimotuzumabHS-20093adebrelimab

    RAS mutation or amplification detected in tumor tissue or blood (by RAS testing).

    KRAS G12CKRAS G12DPancreatic Cancer, RAS Mutations or Amplifications

  2. A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

    Not yet recruiting Phase 1 Hansoh Pharma Started 2025Primary completion 2028-12 NCT06963502

    HS-10370HS-20117adebrelimabcapecitabineoxaliplatinleucovorinfluorouracilirinotecanHS-20093cisplatincarboplatin

    Documentation of the presence of a KRAS G12C mutation

    KRAS G12CAdvanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer